Measures of adherence as predictors of early and total weight loss with intensive behavioral therapy for obesity combined with liraglutide 3.0 mg.

Tronieri JS, Wadden TA, Walsh O, Berkowitz RI, Alamuddin N, Chao AM

Behaviour research and therapy13 May 2020Cited by 15 (Europe PMC)

PMID32450367PMCIDPMC7336389DOI10.1016/j.brat.2020.103639PepBankPUB-32450367

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneObservational studyOther
In adults with obesity treated with intensive behavioral therapy and liraglutide, medication adherence accounted for an additional share of the variance in 52-week weight loss.
In plain wordsIn adults with obesity on behavioral therapy plus liraglutide, how closely people took the medication was linked to how much weight they lost.
Peptide
Liraglutide
Outcome
Not applicableMedication adherence as correlate of 52-week weight loss
Study
n = 100
Outcome group
Body weight · Metabolic and weight
Measurements
Additional variance in 52-week weight loss explained by medication adherence
9.9%
liraglutide-treated participants
Source sentences
Summary
In the 100 liraglutide-treated participants, medication adherence accounted for an additional 9.9% of the variance in 52-week weight loss, and both self-monitoring and medication adherence were independent correlates.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of a randomized trial in which 150 participants (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) received either IBT alone, IBT with liraglutide 3.0 mg/d, or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3245036701
02HumanNot a test of Liraglutide aloneObservational studyOther
In adults with obesity in the multi-component arm (behavioral therapy, liraglutide and meal replacement), meal replacement adherence did not predict weight loss.
In plain wordsIn adults with obesity on behavioral therapy, liraglutide and meal replacement, following the meal replacement plan was not linked to weight loss.
Peptide
Liraglutide
Outcome
No significant changeMeal replacement adherence as predictor of weight loss
Study
n = 50
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
For the 50 Multi-component participants, meal replacement adherence did not predict weight loss.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of a randomized trial in which 150 participants (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) received either IBT alone, IBT with liraglutide 3.0 mg/d, or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3245036702
03HumanNot a test of Liraglutide aloneObservational studyOther
In adults with obesity treated with intensive behavioral therapy and liraglutide, medication adherence remained a correlate of total weight loss after controlling for early weight loss.
In plain wordsIn adults with obesity on behavioral therapy plus liraglutide, taking the medication as planned stayed linked to weight loss after allowing for early weight loss.
Peptide
Liraglutide
Outcome
Not applicableMedication adherence as correlate of total weight loss, controlling for early weight loss
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
However, self-monitoring and medication adherence remained important correlates of total weight loss when controlling for this variable.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a secondary analysis of a randomized trial in which 150 participants (76.1% female, 55.8% white, BMI = 38.8 ± 4.8 kg/m²) received either IBT alone, IBT with liraglutide 3.0 mg/d, or IBT-liraglutide combined with a 12-week meal replacement diet (Multi-component).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3245036703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.